People channel feed

Sage sug­gests job and pipeline cuts af­ter FDA re­jec­tion of ma­jor de­pres­sion pill

Last year
Pharma
FDA+

House E&C chair racks up cam­paign con­tri­bu­tions from more than 30 bio­phar­ma com­pa­nies so far in 2023

Last year
FDA+

Terns Phar­ma­ceu­ti­cal­s' CEO Senthil Sun­daram steps down for health rea­sons

Last year

De­cen­tral­ized tri­als start­up Cure­base scraps clin­i­cal op­er­a­tions busi­ness unit, nar­rows in on soft­ware plat­form

Last year
Startups

In­no­force names De­wan Zeng as the new CEO

Last year
China
Manufacturing

Karyopharm lays off 20% of staff to fo­cus cash on Xpovio can­cer tri­als

Last year

Ex­clu­sive: Tech VC firm Play­ground Glob­al deep­ens biotech fo­cus, hires for­mer a16z part­ner with next fund com­ing

Last year
Financing

Out­sourc­ing com­pa­ny Ster­Rx to shut New York plant and lay off 161 em­ploy­ees due to ‘eco­nom­ic’ rea­sons

Last year
Manufacturing

NIH taps in­fec­tious dis­ease doc­tor Jeanne Mar­raz­zo to suc­ceed Fau­ci as NI­AID head

Last year

In­ter­galac­tic Ther­a­peu­tics, a non-vi­ral gene ther­a­py biotech, lays off all em­ploy­ees

Last year
Startups
Cell/Gene Tx

Af­ter EQRx stint, Ja­mi Ru­bin quick­ly re­turns to CFO post at start­up Bound­less Bio

Last year
Startups

Ri­bon Ther­a­peu­tics rids pre­clin­i­cal work, trims staff to fo­cus on two clin­i­cal PARP in­hibitors

Last year
Startups

As­traZeneca picks up Pfiz­er’s rare dis­ease gene ther­a­pies, taps new R&D leader as Mene Pan­ga­los steps down

Last year
Deals

Ho­mol­o­gy shut­ters de­vel­op­ment as ge­net­ic med­i­cines biotech flash­es ‘for sale’ sign, lays off 80 em­ploy­ees

Last year
R&D
Cell/Gene Tx

Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Last year
R&D

Pfiz­er brings on­col­o­gy R&D leader in­to C-suite, parts ways with de­vel­op­ment chief William Pao af­ter just 16 months

Last year
Pharma

British bil­lion­aire Joe Lewis in­dict­ed for al­leged in­sid­er trad­ing scheme in­volv­ing Mi­rati, Sol­id Bio shares

Last year

The End­points Slack in­ter­view: Lux's Josh Wolfe on AI hype, biotech mar­kets, Twit­ter and more

Last year

Bio­gen ex­pects to re­duce head­count by 1,000 un­der $700M op­er­a­tional sav­ings plan 

Last year

'We sim­ply can­not sus­tain': Idor­sia weighs lay­offs, deals, pipeline trims to bring cost down

Last year

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Last year
R&D

Pas­sage Bio lays off 26% of staff, lets two ex­ec­u­tives go a year af­ter down­siz­ing, lead­er­ship shuf­fle

Last year
Cell/Gene Tx

Affi­ni-T to close Seat­tle lab as it con­cen­trates in Boston, preps two IND fil­ings in next two months

Last year
Startups
Cell/Gene Tx

Stan­ford pres­i­dent re­signs fol­low­ing sci­en­tif­ic mis­con­duct in­ves­ti­ga­tion

Last year
First page Previous page 22232425262728 Next page Last page
A service from the Financial Times